Celcuity INC.
At a glance
EmployeesNot reported
In business since2017
HeadquartersMinneapolis, MN
US patents9
SAM.gov UEIVYHXDAEA9CN5
CAGE code199D2
Incorporated inDE
LEI25490070W7UU7W2SEY87
- targeted therapies
- s first approved product
- REVTORPYK
- HR+/HER2
- PIK3CA Wild-Type locally advanced
- metastatic breast cancer
- PI3K/AKT/mTOR pathway
- commercial-stage biotechnology
- developing
Named on the company’s own website, read JUL 29, 2026
Open positions
Openings read from Celcuity INC.’s own job board on BambooHR, last checked OCT 20, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- Senior or Executive Director, Medical WritingRemote · Clinical Development
- Associate Director, Assay and Process DevelopmentCelcuity INC. · Minneapolis, Minnesota · Research and Development
- Oncology Sales Specialist -Santa Monica/Long Beach, CaliforniaSanta Monica, California, United States · Remote · Commercial
- Senior Director, Analytical ChemistryCelcuity INC. · Minneapolis, Minnesota, United States · Remote · Pharmaceutical Development and Operations
- Associate Director, Congress PlanningRemote · Commercial
- Senior Manager, Clinical SupplyCelcuity INC. · Minneapolis, Minnesota, United States · Remote · Pharmaceutical Development and Operations
- Associate Director/Director, Patient MarketingRemote · Commercial
- Senior or Principal Scientist, Formulation and Process DevelopmentRemote · Pharmaceutical Development and Operations
- Document Control ManagerRemote · Quality Assurance
- Senior Medical Director, Clinical DevelopmentRemote · Clinical Development
Supplier designations
For Profit Organization
Self-certified by the company in its SAM.gov registration
Patents
9 US patents granted 2016–2025, 7 of them in the five years to SEP 2025.
Pharmaceuticals 4Measurement 3Biotechnology 2
- Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]ureaUS 12,350,276 · granted JUL 8, 2025
- Methods of measuring signaling pathway activity for selection of therapeutic agentsUS 12,320,799 · granted JUN 3, 2025
- Methods of preparing a primary cell sampleUS 12,215,356 · granted FEB 4, 2025
- Methods of preparing a primary cell sampleUS 11,591,573 · granted FEB 28, 2023
- Methods of measuring signaling pathway activity for selection of therapeutic agentsUS 11,333,659 · granted MAY 17, 2022
Newest 5 shown · Granted to Celcuity Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Celcuity INC. | Minneapolis | MN | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.